)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aker BioMarine
Aker BioMarine (AKBM) investor relations material
Aker BioMarine has been acquired by Aker
Aker BioMarine Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary10 Jul, 2026
Executive summary
Revenue reached USD 57.9 million in Q2 2026, up 5% year-over-year, with adjusted EBITDA at USD 12.9 million, down 4% from last year.
Human Health Ingredients segment delivered record revenues of USD 34.1 million, up 17% year-over-year, with adjusted EBITDA of USD 15.9 million, up 14%.
Consumer Health Products segment saw revenues decline 6% year-over-year to USD 26.4 million, with adjusted EBITDA at USD 1.1 million.
Net loss for Q2 was USD 5.4 million, compared to a net loss of USD 14.7 million in Q2 2025.
Major new contracts secured for Lysoveta (USD 4 million for China) and Superba (U.S. market, expected to be among top customers).
Financial highlights
Gross margin remained stable overall, though Epion's margin declined due to a new revenue model with Pattern.
SG&A increased in Human Health Ingredients due to investments, but decreased in Consumer Health Products from Epion cost reductions.
Cash flow from operations was negative USD 6.3 million in Q2, mainly due to working capital and nutra meal payment.
Net interest-bearing debt at USD 185 million, up from Q1, mainly due to Nutra settlement.
Equity ratio at 34%, with total equity of USD 135.9 million.
Outlook and guidance
Continued strong growth and improved profits expected for Human Health Ingredients.
Consumer Health Products anticipated to return to modest growth as new product launches are implemented.
Ongoing preparations for a potential transaction in 2026, with no further updates until process conclusion.
Lysoveta expected to see a stream of new customers and market expansion, with EU approval anticipated in early 2027.
Macroeconomic and geopolitical uncertainties may impact energy prices, supply chains, and demand.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aker BioMarine
- Q1 revenue up 13% to USD 57.3M, led by record krill oil sales and improved EBITDA margin.AKBM
Q1 2026 - Q4 2025 saw strong Human Health Ingredients growth and strategic review for future expansion.AKBMQ4 2025
- Q3 revenue up 15% and adjusted EBITDA up 50%, led by Human Health Ingredients growth.AKBMQ3 2025
- Q2 2025 saw double-digit revenue and EBITDA growth, but net profit was hit by a major impairment.AKBMQ2 2025
- Feed Ingredients sale closed, USD 373M dividend paid, and net profit surged to USD 207.5M.AKBMQ3 2024
- Q2 revenue up 6%, $590M Feed Ingredients sale, extraordinary dividend and refi planned.AKBMQ2 2024
- Q1 2025 delivered 5% revenue and 59% EBITDA growth, led by Human Health Ingredients.AKBMQ1 2025
- Q4 revenue up 7% and EBITDA nearly tripled, led by Human Health Ingredients growth.AKBMQ4 2024
Aker BioMarine
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications. Aker BioMarine AS operates through Fish Oils and Pelagic Protein segments. Its products include astaxanthin; fish oil; EPA; acetyl-L-carnitine (ALCAR); omega-3 phospholipids; and omega-3 fatty acids. It also offers products that contain its products that contain astaxanthin in skin care preparations. Aker BioMarine AS markets its products under the AkerBioSolutions brand to food companies and manufacturers of dietary supplements, as well as to producers of livestock feed for hens and pigs.